SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                   FORM 12b-25

                                                 Commission File Number [ 0-935]

                           NOTIFICATION OF LATE FILING

    (Check One):  [ ] Form 10-K and Form 10-KSB   [ ]  Form 11-K   [ ] Form 20-F
                  [X] Form 10-Q and Form 10-QSB   [ ] Form N-SAR

For Period Ended:      September 30, 2003
                  --------------------------------------------------------------

[ ]  Transition Report on Form 10-K and Form 10-KSB
[ ]  Transition Report on Form 11-K
[ ]  Transition Report on Form 20-F
[ ]  Transition Report on Form N-SAR
[ ]  Transition Report on Form 10-Q and Form 10-QSB

For the Transition Period Ended:
                                  ---------------------------------------------

         Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.

         If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:

                         Part I. Registrant Information

Full name of registrant      Molecular Diagnostics, Inc.
                        --------------------------------------------------------

Former name if applicable



Address of principal executive office (Street and number)

                                       414 N. Orleans Street, Suite 510
- --------------------------------------------------------------------------------

City, State and Zip Code    Chicago, IL 60610
                         -------------------------------------------------------




                        Part II. Rule 12b-25 (b) and (c)

         If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check appropriate box.)

[X]      (a) The reasons described in reasonable detail in Part III of this form
         could not be eliminated without unreasonable effort or expense;

[X]      (b) The subject annual report, semi-annual report, transition report
         on Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be
         filed on or before the 15th calendar day following the prescribed due
         date; or the subject quarterly report or transition report on Form
         10-Q, or portion thereof will be filed on or before the fifth calendar
         day following the prescribed due date; and

[  ]     (c) The accountant's statement or other exhibit required by Rule
         12b-25(c) has been attached if applicable.

                               Part III. Narrative

         State below in reasonable detail the reasons why Form 10-K, 10-KSB,
11-K, 20-F, 10-Q, 10-QSB, N-SAR or the transition report portion thereof could
not be filed within the prescribed time period. (Attach extra sheets if needed.)

         Molecular Diagnostics, Inc.'s auditors have not completed their review
of the 10-Q. The auditors have not identified any problems in the report. The
auditors are also awaiting payment for their services.

                           Part IV. Other Information

         (1) Name and telephone number of person to contact in regard to this
notification.

             Peter Gombrich          (312)            222-9550
- -------------------------------------------------------------------------------
         (Name)                 (Area Code)       (Telephone Number)

         (2) Have all other periodic reports required under Section 13 or 15(d)
of the Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).

                                                             [X]  Yes  [  ] No

         (3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or
portion thereof?

                                                            [  ]  Yes  [X] No

         If so: attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.

                           Molecular Diagnostics, Inc.
                  (Name of registrant as specified in charter)

Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.

Date              November 13, 2003       By /S/PETER P.GOMBRICH
    -------------------------------       --------------------------
                                             Peter P. Gombrich
                                             Chairman, Chief Executive Officer